ClinicalTrials.gg
RecruitingNCT07207577THALEXUpdated Oct 7, 2026

Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTD

An interventional study of Maximal incremental exercise test in Beta Thalassemia Transfusion Dependent, sponsored by Centre Hospitalier Metropole Savoie. Recruiting at 1 site in France. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-07.

Sponsored by Centre Hospitalier Metropole Savoie · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in beta-Thalassemia with a site in France — 2 open to participants now, 5 under way, 3 of them phase 3. beta-Thalassemia · France.

Planned enrollment
6th of 10
36 · median 41
Started
2025
the only one that year
No phase
2 of 11
1 open now
Registered
11th of 11
by date
Lead sponsor
1 of 11
Centre Hospitalier Metropole Savoie

Among the 11 studies in beta-Thalassemia with a site in France, this one is the 6th largest by planned enrollment of the 10 interventional ones that give a count, is the only one that started in 2025, is one of 2 with no phase, and was the 11th registered.

beta-Thalassemia

295 studies on the registry are indexed under beta-Thalassemia; 70 are open to participants now.

Browse beta-Thalassemia studies →

Open to participants now

2 of the 11 studies in beta-Thalassemia with a site in France are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in beta-Thalassemia with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to compare physical ability of patients with transfusion-dependent β-thalassemia to control subjects. The main question it aims to answer is:

is there a difference in power output at first lactate threshold between patients with transfusion-dependent β-thalassemia and control subjects during maximal incremental exercise test.

Participants will have to realise differents exams including measurement of body compposition, maximal incremental exercise test, vertical jump, vasoreactivity test, blood sampling, quality of life questionnaires and neuromuscular assessments.

03

Conditions studied

  • Beta Thalassemia Transfusion Dependent

Browse trials for

Keywords

  • physical ability
  • Beta thalassemia transfusion dependent
  • control subjects
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 years or older

    • Patients with transfusion-dependent β-thalassaemia (B0 or B+)
    • Patients who have undergone blood transfusions at intervals of between 1 and 8 weeks for at least 5 years.
    • Have given their free and informed written consent after being informed of the purpose of the study, its conduct and its risks.
    • Be affiliated with a social security scheme.
    • Not participating in any other interventional studies during the duration of this study

Control subjects must meet all of the following criteria to participate in the study:

  • Subject aged 18 years or older
  • Matched in age and gender to a βTTD patient included in the study.
  • Declaring to be free of known acute or chronic pathologies.
  • Have given their free written consent after being informed of the purpose of the study, its conduct and its risks.
  • Be affiliated with a social security scheme.
  • Not participate in any other interventional study during the duration of this study.
  • Have 'low' or 'moderate' IPAQ results (inactive or slightly active).

Exclusion criteria

Exclusion Criteria:

  • - Having received a bone marrow transplant.
  • History of thromboembolic disease.
  • Hospitalised for cardiac decompensation in the last 12 months.
  • Lack of use of limbs (amputee, paraplegic, quadriplegic)
  • Unable to comply with protocol requirements for social, family or other reasons, as determined by the investigator.
  • Known concomitant medical condition that could affect compliance with the protocol
  • benefiting of enhanced protection, namely minors, persons deprived of their liberty by judicial or administrative decision, adults under legal protection and, finally, patients in emergency situations.
  • Unable to give consent.
  • Pregnant or breastfeeding women.
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
36 participants (estimated)

Study arms

  • Other
    Control group

    control participant without Beta thalassemia

    Other: Maximal incremental exercise test

  • Experimental
    Beta thalassemia transfusion dependent

    same intervention than control group

    Other: Maximal incremental exercise test

Interventions

  • OtherMaximal incremental exercise test

    Participants will perform a symptom-limited maximal incremental exercise test on a cycle ergometer.

06

What researchers measure

Primary outcomes

  1. Power at the first lactate threshold (PSL1) collected during the maximal incremental exercise test, compared between the two groups

    Participants perform a maximal incremental exercise test on a cycle ergometer. The protocol includes one-minute intervals, with increments and initial power varying according to the subject's age and gender. The exercise continues until the subject is unable to maintain the power imposed by the current level. A drop of blood sample is taken from the earlobe and immediately analyzed to measure blood lactate concentration and determine first lactate threshold.

    Time frame: 7 days after a transfusion for patient

Secondary outcomes

  1. Comparison of power values at lactate threshold 2 between βTTD patients and control subjects.

    During the exercise test, a drop of blood is taken from the earlobe and immediately analyzed to measure blood lactate concentration and determine secondlactate threshold (LT2).

    Time frame: 7 days after a transfusion for patients

  2. Comparison between βTTD patients and control subjects of oxygen consumption efficiency slope values (OUES for Oxygen Uptake Efficiency Slope)

    Cardio-pulmonary parameters are measured continuously throughout the maximum incremental exercise test and are used to calculate, among other things, the oxygen uptake efficiency slope (OUES), an indicator of the subject's ability to transport and use oxygen.

    Time frame: 7 days after a transfusion for patients

  3. Comparison between βTTD patients and control subjects of cardiac output values combining heart rate and systolic ejection volume values during maximal exercise.

    Values will be recorder during maximal incremental exercise test. Heart rate and systolic ejection volume values is continuously recorded by bioimpedance measurement.

    Time frame: 7 days after a transfusion for patients

  4. Comparison of muscle mass values between βTTD patients and control subjects

    A body composition measurement will be performed using bioimpedance analysis.

    Time frame: 7 days after a transfusion for patients

  5. Comparison between βTTD patients and control subjects of first-second expiratory flow values (FEV1, L)

    A spirometry test will be performed. After taking a deep breath, the participant will be asked to exhale as quickly as possible into the spirometer.

    Time frame: 7 days after a transfusion for patients

  6. Comparison between βTTD patients and control subjects of maximum grip strength, jump height and reactive strength index values

    Jump height will be evaluate using video analysis.

    Time frame: 7 days after a transfusion for patients

  7. Compare neuromuscular function between βTTD patients and control subjects

    Nerve conduction will be assessed by electroneuromyography (ENMG). Muscle electrical activity will be measured by ENMG following low-intensity electrical stimulation to collect the F wave. This test will measure: nerve conduction velocity, latency between nerve stimulation and response, response amplitude, and response duration.

    Time frame: 7 days after a transfusion for patients

  8. Compare the level of physical activity between βTTD patients and control subjects

    Level of activvity will be assessed with of International Physical Activity Questionnaire

    Time frame: During inclusion visit, at day 1

  9. Compare anxiety levels between βTTD patients and control subjects.

    score to HADS questionnaire

    Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.

  10. Comparison between βTTD patients and control subjects of muscle reoxygenation slope values upon removal of arterial occlusion

    A vasoreactivity test will then be performed at rest following venous occlusion, in order to measure the ability to reoxygenate the tissue.

    Time frame: 7 days after a transfusion for patients

  11. Correlation within the βTTD group between physical ability and cardiac iron load, hepatic iron load and EPO

    Correlation within the βTTD group between power at lactate threshold 1 (see primary outcome) and cardiac T2\* , hepatic iron concentration and EPO level wich will be taken in patient medical file

    Time frame: 7 days after a transfusion for patients

  12. Correlation within the βTTD group between testosterone (men) or oestrogen (women) levels and muscle mass in kg

    data collected in patient medical file

    Time frame: 7 days after a transfusion for patients

  13. Correlation within the βTTD group between quality of life and physical ability

    SF36 questionnaire will be done and scoore will be correlated to power at first lactic threshold

    Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.

  14. Assessing the link between perceived fatigue and physical activity levels in βTTD patients

    Correlation between the score at FACIT-F questionnaires compared to scores at IPAQ questionnaires

    Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.

  15. Assessing the link between physical fitness and fatigue/pain experienced by βTTD patients

    Correlation within the βTTD group between power at lactate threshold 1 and FACIT-F and BPI scores (multivariate analysis).

    Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.

  16. Assessing the link between microvascular vasoreactivity, inflammation and haemolysis in βTTD patients

    Correlation within the βTTD group between the reoxygenation slope and blood concentrations of CRP, LDH, and indirect bilirubin

    Time frame: 7 days after transfusion for patients

  17. Assessing motivation for physical activity in βTTD patients

    Description of the EMAPS score

    Time frame: During second visit, occuring during a transfusion visit and no longer than 3 months after the inclusion.

  18. Comparison between βTTD patients and control subjects of vital capacity (VC, L)

    A spirometry test will be performed. After taking a deep breath, the participant will be asked to exhale as quickly as possible into the spirometer.

    Time frame: 7 days after a transfusion for patients

  19. Comparison between βTTD patients and control subjects of maximum exercise ventilation (VE, L.min-1)

    The ventilation rate will be continuously monitored during CPET. The ventilation rate value corresponding to the time of maximal exercise based on oxygen consumption will be used.

    Time frame: 7 days after a transfusion for patients

  20. Comparison between βTTD patients and control subjects of maximum grip strength (kg)

    Maximum grip strength will be assessed with a hand dynamometer.

    Time frame: 7 days after a transfusion for patients

  21. Comparison between βTTD patients and control subjects of reactive strength index values

    Reactive strength index values will be calculated based on jump height divided by the time to take-off

    Time frame: 7 days after a transfusion for patients

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Noguer M, Berthon P, Makowski C, Messonnier LA. Impaired physical ability in patients with transfusion-dependent beta-thalassaemia: Can regular physical activity be a countermeasure? Br J Haematol. 2025 Jan;206(1):86-93. doi: 10.1111/bjh.19847. Epub 2024 Nov 19. PubMed 39562756 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Oct 2028, 37 months after the start.

Of 29 interventional studies with no phase under beta-Thalassemia, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 69. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 6, 2025
StartActual
Sep 4, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Oct 2028
Last update
Oct 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: identifiers and verification date
1 update, last Oct 7, 2026
Show all 1 update
  1. Oct 7, 2026
    Minor edits only
    + 2 other changes: identifiers and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07207577
Lead sponsor
Centre Hospitalier Metropole Savoie
Collaborators
Université Savoie Mont Blanc, Laboratoire de Psychologie et NeuroCognition (LPNC), Université Grenoble Alpes
Responsible party
Sponsor
First posted
Oct 6, 2025
Start date
Sep 4, 2025
Primary completion
Oct 2028 (estimated)
Completion
Oct 2028 (estimated)
Last update
Oct 7, 2026

Study contacts

Charlene DUPRE
Contact
charlene.dupre@ch-metropole-savoie.fr
+33479965910
Leo BLERVAQUE
Contact
leo.blervaque@ch-metropole-savoie.fr
+33479965910
Laurent MESSONNIER
study chair · Université Savoie Mont Blanc
Pierre FAURIE
principal investigator · CH Metropole Savoie
Mathilde NOGUER
study chair · Université Savoie Mont Blanc

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion